Expression of YAP1 in aggressive thyroid cancer

Authors :: Saverio Massimo Lepore
Cosimo Durante
Valentina Maggisano
Antonella Verrienti
Giuseppe Damante
Diego Russo
Marilena Celano
Marialuisa Sponziello
Carla Di Loreto
Michelangelo Iannone
Francesca Rosignolo
Giovanni Enrico Lombardo
Stefania Bulotta
Chiara Mignogna
Source :: Endocrine (Basingstoke) (2017). doi:10.1007/s12020-017-1240-6, info:cnr-pdr/source/autori:Celano M, Mignogna C, Rosignolo, Sponziello M, Iannone M, Lepore SM, Lombardo GE, Maggisano V, Verrienti A, Bulotta S, Durante C, Di Loreto C, Damante G, Russo D./titolo:Expression of YAP1 in aggressive thyroid cancer/doi:10.1007%2Fs12020-017-1240-6/rivista:Endocrine (Basingstoke)/anno:2017/pagina_da:/pagina_a:/intervallo_pagine:/volume
Publication Year :: 2016
Abstract: The Hippo signal transduction pathway plays a crucial role in the control of cellular proliferation, so that its deregulation is believed to be involved in neoplastic transformation [1, 2]. A wide array of human cancers show a down-regulation of Hippo pathway, resulting in the activation of the co-transcription factors Yes-associated protein (YAP1) as well as the transcriptional coactivator with PDZ-binding motif (TAZ). In turn, the YAP/TAZ complex increases transcription of target proteins with oncogenic activity [1, 2]. Thus, targeting YAP has been tested to arrest cancer cell proliferation [3, 4].

Tools